Aditxt, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219
Mailing Address 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219
Phone 909-488-0844
Fiscal Year End 1231
EIN 823204328
Financial Overview
FY2024 FY
$645K
Revenue
$-3062.51
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | December 16, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 12, 2025 | View on SEC |
| 8-K Current report of material events | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 18, 2025 | View on SEC |
Material Events
8-K Financial Distress February 13, 2026
High Impact
- Shareholders authorized the board to implement a reverse stock split (1-for-5 to 1-for-250) to meet NASDAQ listing requirements.
- Approval for issuing common shares to fulfill past funding agreements, converting preferred stock and warrants.
8-K Strategy Change January 30, 2026
High Impact
- Seeking to maintain NASDAQ listing compliance through a reverse stock split.
- Proposing a potential strategic rebranding and pivot with a name change to 'bitXbio, Inc.'
8-K Financial Distress January 28, 2026
High Impact
- Aditxt secured a Nasdaq extension, providing a conditional lifeline to regain compliance with listing standards.
- The company has submitted a plan to Nasdaq focusing on completing financing transactions to bolster its capital base and improve stockholders' equity.
8-K Financial Distress December 5, 2025
High Impact
- Aditxt, Inc. received a notice from Nasdaq for failing to meet Listing Rule 5550(b)(1), as its stockholders' equity fell below the required $2.5 million minimum.
- The company faces potential delisting from Nasdaq if it cannot regain compliance with the financial requirement.
Insider Trading
SELL 2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Werewolf Therapeutics, Inc.
HOWL Pharmaceutical Preparations
Zenas BioPharma, Inc.
ZBIO Pharmaceutical Preparations
Centessa Pharmaceuticals plc
CNTA Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI Pharmaceutical Preparations
VERTEX PHARMACEUTICALS INC / MA
VRTX Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.